Scribe Therapeutics, Inc. (SCTX) stock
SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)
Close on Nov 17, 2026Market cap $39.19MP/E –Yield –
Scribe Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Scribe Therapeutics's enterprise value was -$1.10M on Nov 11, 2026.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$1.10M | – |
See a number that looks wrong?